1Brawer M K, Cheter M P, Beatie J, et al. Screening for prostatic carcinoma with prostate specific antigen [J]. J Urol, 1992, 147:841-845.
2Khan M A, Carter H B, Epstein J I, et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer[J]? J Urol, 2003, 170:2274-2278.
3Roobol M J, Kranse R, de Koning H J, et al. Prostare-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM) [J]. Urology, 2004, 63:309-313.
4Thompson I M, Pauler D K, Goodman P J, et al.Prevalence of prostate cancer among men with a prostate-specific antigen level < or=4.0 ng per milliliter [J]. N Engl J Med, 2004, 27,350:2239-2246.
5Kobayashi T, Nishizawa K, Ogura K, et al. Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/ml equivalent to that in men with 4.1 to 10.0 ng/ml in a Japanese population. Urology,2004,63:727-731.
6Brawe M K. The diagnosis of prostatic carcinoma[J].Cancer, 1993, 71: 899-905.
7Masaaki Kuwahara, TaTsua Tochigi, Ning X U, et al.Mass screening for prostate cancer: a comparative study in Natori, Japan and Changchun, China[J]. Urology, 2003,61:137-141.
8Catalona W J, Richie J P, deKernion J B, et al. Comparison of prostate specific antigen concentration versus prostate cancer: receiver operating characteristic curves[J]. J Urol,1994, 152:2031-2036.
9Matsuyama H,Baba Y, Yamakawa G, et al. Diagnostic value of prostate-specific antigen-related parameters in discriminating prostate cancer[J]. Int J Urol, 2000, 7:409-414.
10Naragan P, Gajendran V, Taylor S P, et al. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum PSA, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancerl[J]. Urology, 1995, 46:205-212.
